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controlling effector T cell proliferation and
motility in the CNS
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Regulatory T cells are crucial in controlling various functions of effector T cells during experimental autoimmune
encephalomyelitis. While regulatory T cells are reported to exert their immunomodulatory effects in the peripheral
immune organs, their role within the central nervous system (CNS) during experimental autoimmune
encephalomyelitis is unclear. Here, by combining a selectively timed regulatory T cells depletion with 2-photon
microscopy, we report that regulatory T cells exercise their dynamic control over effector T cells in the CNS. Acute
depletion of regulatory T cells exacerbated experimental autoimmune encephalomyelitis severity which was accompanied
by increased pro-inflammatory cytokine production and proliferation of effector T cells. Intravital microscopy revealed that,
in the absence of regulatory T cells, the velocity of effector T cells was decreased with simultaneous increase in
the proportion of stationary phase cells in the CNS. Based on these data, we conclude that regulatory T cells mediate
recovery from experimental autoimmune encephalomyelitis by controlling cytokine production, proliferation and
motility of effector T cells in the CNS.
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CD4+Foxp3+ regulatory T cells (Treg) have a well-
characterized role in promoting peripheral immunological
tolerance throughout life by suppressing deleterious in-
flammatory responses [1]. Lack of Treg due to mutations
in the FOXP3 gene in humans results in aggressive multi-
organ autoimmunity called IPEX (immunodysregulation,
polyendocrinopathy, enteropathy, X-linked) syndrome [2].
Similarly, scurfy mice, which harbor mutations in the
Foxp3 gene, or Foxp3-gene deficient mice suffer from a
massive lymphoproliferative syndrome [3,4]. Targeted de-
pletion of Treg also resulted in severe multi-organ auto-
immunity [5,6]. Intriguingly, however, no spontaneous
central nervous system (CNS) inflammation was observed
in Foxp3 mutant mice or after targeted depletion of Foxp3
+Treg cells in wild type mice [7].
Treg have been demonstrated to be capable of controlling
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population within the CNS were elevated during the recov-
ery phase of actively induced EAE [8-10]. Moreover, several
studies described that the transfer of CD25+ Treg amelio-
rated EAE symptoms [9,11-13]. In addition, non-specific
ablation of natural Treg by anti-CD25 antibodies has been
reported to exacerbate EAE [9,14-16]. Furthermore, Treg
have been shown to prevent spontaneous EAE develop-
ment [17,18] or delay spontaneous EAE onset [19].
Where and how do Treg exert their control over
myelin-specific T cells? In principle, Treg could suppress
effector T cells (Teff ) in the periphery or within the tar-
get organ, CNS. One report demonstrated that Treg ac-
cumulate in the CNS at the peak of EAE but were
unable to suppress CNS-derived Teff in vitro [8]. In con-
trast, Treg isolated from the recovery phase of the disease
were still capable of suppressing Teff [10]. Furthermore,
another study reported that, in the absence of Treg, there
is an enhanced migration of Teff from the periphery [19].
Treg are known to limit the inflammatory reactions using
several mechanisms that include soluble mediators, cell-
to-cell contact with Teff or inhibiting antigen presentingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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priming and polarization of Teff [11,20]. Among soluble
cytokines produced by Treg, IL-10 is important in con-
taining Teff proliferation in vitro [16]. Treg can also set a
threshold for activation of autoreactive Teff by inhibiting
their contacts with antigen-loaded dendritic cells (DCs)
in the lymph nodes [21-23]. Furthermore, Treg have been
shown to contact and inhibit DCs in vitro via CTLA-4
[24]. However, the mode of action of Treg during CNS
autoimmunity, in particular within the target organ, still
remains unclear.
To address those principal outstanding issues, in the
present study, we combine targeted and acute depletion of
Treg with intravital two-photon microscopy to investigate
the functional role of Treg in the CNS during EAE. We
found that Treg limit autoimmune inflammation by con-
trolling the Teff proliferation and motility within the CNS.
Material and methods
Animals
DEREG [6] and T-Red [25] mice with the C57BL/6 gen-
etic background were used. All mice were bred in the
animal facility of the Max Planck Institute of Neurobiol-
ogy and all experiments were conducted according to the
guidelines of the committee on animals of the Max Planck
Institute of Neurobiology and were approved by the Regier-
ung von Oberbayern.
EAE induction and diphtheria toxin treatment
EAE was induced by injecting the mice subcutaneously
into the flanks with 200 μl of emulsion containing
200 μg MOG35–55 peptide (MEVGWYRSPFSRVVH-
LYRNGK) and 500 μgM. tuberculosis strain H37 Ra
(Difco) in incomplete Freund Adjuvant oil (Difco). In
addition, the mice received 400 ng pertussis toxin (List
Biological Laboratories) intraperitoneally (i.p.) on days
0 and 2 after immunization. Clinical signs of EAE were
assessed daily according to the standard 5 point scale
[26]. For depletion of Treg in DEREG mice, diphtheria
toxin (Sigma-Aldrich) was injected both i.p. and i.v.
(200 ng respectively) on day 4 post EAE onset.
Cell isolation and flow cytometry
Cells from lymph nodes and spinal cord were isolated as
described before [26]. For detection of cell surface markers,
cells were stained in FACS buffer (PBS containing 1% BSA
and 0.1% NaN3) with the following fluorochrome labeled
monoclonal antibodies: anti-CD45 (30-F11), anti-CD4
(RM4-5), anti-CD25 (PC61) and anti-CD44 (IM7). For
intracellular cytokine staining, cells were incubated for
16 hours with anti-CD3 (0.5 μg/ml). Next, cells were fixed
and permeabilized by incubation with Foxp3 Fixation/
Permeabilization Buffer (eBioscience) and stained in
Permeabilization Buffer (eBioscience) with the followingfluorochrome labeled monoclonal antibodies: anti-Foxp3
(FJK-16s), anti-IL-17 (eBio17B7) and anti-IFNγ (XMG1.2).
All antibodies were purchased from BD Pharmigen or
eBioscience. For cell number quantification, 104 FACSuite
FC Beads (BD) were added per sample prior to acquisition.
Samples were acquired on FACS Verse (BD). FACS data
were analyzed using FlowJo 7.6.5 software (TreeStar).
EdU proliferation assay
For in vivo proliferation experiments, 400 μg EdU (Life
Technologies) were injected i.p. to mice ~16 hours be-
fore their sacrification. The Click-iT® EdU Alexa Fluor®
647 Flow Cytometry Assay Kit (Life Technologies) was
used for staining for flow cytometry according to manu-
facturer’s instructions.
Immunofluorescence
The organ sections were prepared as described previously
[27]. The following monoclonal antibodies were used for
staining: biotin-anti-CD4 (RM4-5; BD), Alexa Fluor 647-
anti-CD11b (M1/70; Biolegend), Alexa Fluor 488-anti-
Foxp3 (FJK-16 s; eBioscience), and Alexa Fluor 568-
streptavidin (Invitrogen). Images were acquired on a SP5
confocal microscope (Leica), using 20x air-immersion (N.
A. 0.70) or 63x oil-immersion (N.A. 1.4) objective. Images
were processed using Image J (NIH) and Photoshop CS5
software (Adobe Systems).
In vivo IL-2 blocking
MOG35–55/CFA-immunized DEREG B6 mice were treated
with DTx, as described above. Purified anti-IL2 (JES6-
1A12) monoclonal antibody or isotype control antibody
(J1.2) was injected i.v. on day 4 (400 μg) and day 6 (200 μg)
post EAE onset.
Intravital imaging
The technical setup of the 2-photon microscopy was as
described before [28]. The pulsed laser was tuned to
880 nm and routed through a 25× water immersion ob-
jective (N.A. 0.95, Leica). Typically, a field of 360 ×
360 μm was scanned, and 40–80 μm z-stacks were ac-
quired using a 3–6 μm z-step. The acquisition rate was
set to 25.219 s intervals, with images line-averaged
twice. The fluorescence signals were detected using
non-descanned photomultiplier tube (PMT) detectors
(Hamamatsu) equipped with 525/50 nm (for detection of
Alexa Fluor 488) and 630/69 nm (for detection of dsRedII)
band-pass filters (Semrock). Mice were anesthetized and
imaging in the spinal cord was performed as described
previously [28]. For labeling of perivascular meningeal
APC, we performed local instillation of Alexa Fluor 488–
conjugated dextran (10 ng/μl, 10 kDa; Life Technologies)
20 min prior to imaging, as described before [29]. Image
analysis was performed as described previously [29].
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Statistical evaluations were performed as indicated in
figure legends using GraphPad Prism software.
Results and discussion
Our approach to analyze the role of Treg in vivo during
EAE differs from previous attempts which have used
anti-CD25 antibodies [9,14-16]. Since these antibodies
persist in the circulation for long time, their effect on
CD25-expressing activated Teff cannot be excluded. To
investigate the functional role of Treg in the CNS during
peak EAE, we chose DEREG mice which express a diph-
theria toxin (DTx) receptor-enhanced GFP fusion protein,
under the control of the Foxp3 gene locus, permitting spe-
cifically timed depletion of Treg by treatment with DTx
[6]. We immunized DEREG mice with MOG35–55 in CFA
and treated them with DTx or PBS during peak of the dis-
ease. We monitored the efficiency of Treg depletion in per-
ipheral immune organs and the CNS by flow cytometry.
Staining for Foxp3 revealed that Treg population was al-
most completely absent in DTx-treated DEREG miceFigure 1 Exacerbation of EAE after acute Treg depletion at the peak o
frequency (± SEM) of Foxp3+ in CD45+CD4+ T cells (B) isolated from indica
shown (n = 11 mice per group, pooled data from four independent experim
and DTx or PBS treatment (day 4 post EAE onset). (n = 6-7 mice per group,
****P < 0.0001, 2way ANOVA).compared to control animals in all the organs tested
(Figure 1A,B). Next, immunized and treated mice were
monitored daily for clinical score to assess the effect of
Treg depletion on EAE pathogenesis. While PBS-treated
DEREG mice partially recovered from EAE, DTx-
treated DEREG mice not only failed to recover from the
disease, but also developed severe and, eventually, fatal
EAE (Figure 1C). To rule out any adverse effect of DTx on
EAE disease course, we have treated MOG35–55 immunized
wild type mice with DTx during peak EAE. Unlike in
DEREG mice, the EAE course was not affected compared
to control mice (Additional file 1: Figure S1). These find-
ings suggest that Treg contribute to recovery from EAE and
perhaps have an essential function within the CNS.
To learn how Treg ablation led to dramatic disease ex-
acerbation, we stained spinal cord sections of the mice
two days after the treatment with DTx or PBS. We ob-
served highly increased numbers of Teff, as well as mac-
rophages, in the spinal cord infiltrates in Treg-depleted
mice compared to the control animals (Figure 2A-F).
Next, we quantified the numbers of CD45+CD4+Foxp3−f the disease. Representative flow cytometry plots (A) or mean
ted organs of DEREG mice two days after DTx or PBS treatment are
ents). (C) Mean clinical score (± SEM) of mice following immunization
representative data from two independent experiments. **P < 0.01,
Figure 2 Increased numbers and enhanced proliferation of Teff in Treg-depleted mice. (A), (D) Representative panoramic pictures of spinal
cord cryosections from mice treated with DTx (A) or PBS (D) stained with anti-Foxp3 (green), anti-CD4 (red) and anti-CD11b Ab (grey) (scale bar:
200 μm). (B), (C), (E), (F) Magnified pictures of the indicated regions (A) and (D) (scale bar: 50 μm). (G) Mean absolute numbers (± SEM) of Teff
(CD45+CD4+Foxp3− cells) isolated from LN and spinal cord of DEREG mice two days after DTx or PBS treatment (n = 11 mice per group, pooled
data from three independent experiments). (H) Mean frequency (± SEM) of IFNγ+ cells in Teff isolated from LN and spinal cord of DEREG mice
two days after DTx or PBS treatment (n = 5 mice per group, representative data from three independent experiments) (I) EdU was injected i.p.
one day after DTx or PBS treatment and 16 hours later lymphocytes were isolated and stained for EdU. Mean frequency (± SEM) of EdU+ cells
within Teff (n = 13-14 mice per group, pooled data from four independent experiments). (*P < 0.05, **P < 0.01, t-test).
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as in the spinal cord, using flow cytometry. Interestingly,
lymph nodes and spinal cord of Treg-depleted mice con-
tained significantly elevated numbers of Teff (defined as
CD45+CD4+Foxp3− T cells) compared to control mice
(Figure 2G). In addition, DTx-treated mice displayed
higher frequencies of pro-inflammatory cytokine IFNγ-
secreting Teff in the CNS and LN (Figure 2H). In con-
trast, we detected similar frequencies of IL-17+ Teff in
both groups. We also did not observe differences in the
percentage of activated CD25+CD44high Teff in DTx-treated mice (Additional file 1: Figure S2). Therefore, the
exacerbated EAE pathology observed in Treg-depleted
mice could be attributed to increased fraction of IFNγ-
producing Teff in the CNS.
Treg are known to suppress the proliferation and acti-
vation of Teff cells through multiple mechanisms [1].
Lack of functional Treg results in a lymphoproliferative
disease, as in scurfy mutant mice [30]. Similar fatal lym-
phoproliferative disease was observed after chronic de-
pletion of Treg in adult and neonatal mice [5,6]. To
determine if the elevated numbers of Teff were a result
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proliferation of Teff in the presence or absence of Treg.
One day after the DTx or PBS treatment of immunized
DEREG mice, we injected EdU (5-ethynyl-2´-deoxyuridine),
a thymidine analogue which is readily incorporated into
cellular DNA during DNA replication, and examined the
EdU incorporation in T cells by flow cytometry (Figure 2I).
The fraction of EdU+ Teff was significantly higher in both
LN and the spinal cord of DTx-treated mice compared to
control mice, suggesting that the Teff proliferation during
EAE is enhanced in the absence of Treg.
Since we observed an increased proliferation of Teff in
the CNS, we focused on the role of IL-2, a pivotal cyto-
kine for T cell proliferation. Treg express high levels of
high affinity IL-2 receptor α (CD25), thereby restricting
the availability of IL-2 by direct consumption to restrain
the activation of proliferating T cells [31]. We hypothe-
sized that the enhanced Teff proliferation that we ob-
served after elimination of Treg could be attributed to
increased availability of IL-2. To test this hypothesis, we
quantified the IL-2 protein levels in LN and spinal cordFigure 3 Teff dynamics in the CNS of Treg-depleted mice. Intravital two
x DEREG mice two days after DTx or PBS treatment. (A) Trajectories (white
videos. One representative out of three independent experiments per trea
(B) Superimposed trajectories of Teff movements after DTx or PBS treatme
respectively. One representative out of three independent experiments per tre
of the total displacement divided by the path length of a cell), (E) stationary p
or PBS treatment (pooled data from three independent experiments (**P < 0.0tissue extracts from Treg-depleted and Treg-intact mice
with EAE. However, both groups exhibited similar levels
of IL-2 (Additional file 1: Figure S3A). Furthermore, ad-
ministration of anti-IL-2 blocking antibodies in parallel
with DTx treatment did not prevent EAE exacerbation
(Additional file 1: Figure S3B). These findings suggest
that IL-2 deprivation is not a major mechanism used by
Treg to control Teff proliferation in vivo within the CNS
during EAE.
We considered the possibility of direct or indirect inter-
actions of Treg with Teff and APCs to mediate suppression
of Teff in the CNS during EAE recovery. Previous 2-
photon imaging studies in LN have shown that Treg can
limit the contacts between Teff and DCs [21-23]. However,
the effect of Treg on the migratory behavior of Teff within
the CNS during EAE is not known. We sought to investi-
gate how the ablation of Treg can affect the dynamic be-
havior of Teff in the CNS using intravital two-photon
imaging. To this end, we crossed T-Red mice, in which T
cells express the red fluorescent protein dsRedII [32], to
DEREG mice. Subsequently, we treated MOG-immunized-photon imaging was performed in the spinal cord meninges of T-Red
lines) of dsRedII+ Teff overlaid with snapshots from representative
tment condition is shown (red: Teff, green: APC, scale bar: 30 μm)
nt. Time points with contacts with APC are indicated in red or blue,
atment condition is shown. (C) Average velocity, (D) linearity index (sum
hase (part of the track with velocity <3 μm/min) (± SEM) of Teff after DTx
1, t-test) (pooled data from three independent experiments).
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EAE and performed intravital two-photon imaging in the
spinal cord meninges.
Cell tracking of the dsRedII-expressing Teff revealed that
Teff displayed more confined trajectories in the CNS of
DTx-treated mice than PBS-treated mice (Figure 3A,B).
Indeed, analysis of the Teff tracks showed that the cells
had significantly reduced mean velocity and linearity
index compared to the control animals in the CNS
(Figure 3C,D). In parallel, the stationary phase of Teff
was increased (Figure 3E). Collectively, these findings
suggest that the absence of Treg results in decreased
motility of Teff, which indicates enhanced interactions
with potential APCs within the inflamed spinal cord
meninges.
In summary, using 2-photon imaging, we showed that
Treg exert dynamic control over Teff within the CNS dur-
ing effector phase of EAE. This finding doesn’t exclude
additional actions mediated by Treg in the periphery.
Our results are in agreement with many reports which
showed that ablation of Treg population (by treatment
with anti-CD25 antibody) exacerbates EAE [9,14-16].
However, a major disadvantage of this approach is that
CD25 is not a Treg-specific marker, but is also expressed
by activated Teff complicating the interpretation of these
findings. Our approach using DEREG mice circumvents
these issues by specifically timed depletion of Treg. This
is also a first study in an active EAE which uses specific
Treg depletion. Our results are compatible with a recent
report which showed that selective Treg depletion re-
sulted in an increased incidence and accelerated disease
onset in a spontaneous EAE model [19].
While the importance of Treg during CNS auto-
immunity is unequivocally shown, where and in which
phase of the disease they are important is not clear. The
main conclusion from our study is that the Treg exert
their regulatory control over Teff within the CNS in
addition to their known peripheral effects. At first
glance, our results are in contrast to a report by Korn
et al., which suggested that regulatory T cells accumulate
in the CNS but are unable to control CNS infiltrating
Teff during peak of the disease [8]. The conclusions were
drawn based on the inability of CNS derived Treg to sup-
press Teff proliferation. We, however, have followed the
behavior of Teff cells in their “native” environment.
Moreover, several studies reported that natural recovery
from EAE correlating with increasing Treg numbers sug-
gests that Treg are essential to mediate recovery [8-10].
Concerning the potential mode of action, we observed
that the exacerbation of EAE was preceded by an in-
crease in the numbers of Teff due to local proliferation
in the absence of Treg. Earlier reports using two-photon
microscopy have demonstrated that CD4+CD25− T cells
established longer contacts with DCs in lymph node inthe absence of Treg (defined as CD4
+CD25+ T cells),
while in Treg-sufficient environment these contacts were
inhibited [22,23]. Moreover, Treg have been recently de-
scribed to suppress the T cell movements in the LN dur-
ing EAE in a PSGL-1-dependent mechanism [21]. Our
results show that there is an increase in the motility of
Teff in Treg-depleted mice and there was an increase in
the stationary phase of Teff, indicating increased contacts
with APCs in the CNS. In conclusion, our findings sug-
gest that Treg are indispensable for recovery from EAE
through their actions within and outside of the CNS.
Additional file
Additional file 1: Figure S1. DTx injection does not affect EAE course
in non-transgenic mice. Mean clinical score (± SEM) of mice following
immunization and DTx or PBS treatment (day 4 post EAE onset). (n = 5-6
mice per group, representative data from two independent experiments.
Figure S2. Expression of IL-17 and T cell activation markers in Treg-depleted
mice. (A) Mean frequency (± SEM) of IL-17+ cells in Teff isolated from LN and
spinal cord of DEREG mice two days after DTx or PBS treatment (n = 5 mice
per group, representative data from three independent experiments) (B)
Mean frequency (± SEM) of CD25+CD44high cells within Teff isolated from LN
and spinal cord of DEREG mice two days after DTx or PBS treatment (n = 8
mice per group, pooled data from two independent experiments).
Figure S3. Treg do not use IL-2 deprivation to limit Teff proliferation.
(A) IL-2 protein levels (± SEM) in LN and spinal cord of DEREG mice
two days after DTx or PBS treatment (n = 5 mice per group, pooled
data from two independent experiments). (B) Mean clinical score
(± SEM) of mice following immunization and DTx treatment (day 4
post EAE onset) as well as anti-IL2 antibody treatment on days 4 and 6
post EAE onset (see arrow) (n = 3-4 mice per group, representative
data from two independent experiments).
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